H.R. 1262
Expands pediatric cancer drug research and FDA oversight
Lets the FDA allow tests of new cancer drugs in combination with already-approved medicines in children, and lets the FDA act against drug makers that skip required pediatric studies.
- Allows pediatric cancer research on new drugs combined with already-approved ingredients
- Lets the FDA penalize sponsors that fail pediatric study requirements without good effort
- Renews prizes for quick review of new rare childhood disease treatments through September 2029
- Funds priority children's research at the National Institutes of Health through 2027
Passed the House · Senate's turn